BioLineRx Ltd. (TASE: BLRX)
Health Care · Biotechnology · IL
₪0.02
+6.67% today · -23.8% 1Y
BioLineRx Ltd. (TASE: BLRX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $14.03M and employs 22 people.
Over the last twelve months the share price has lost 23.8%, trading between 0.01 and 0.02.
Tweenvest scores BioLineRx Ltd. across four factors: quality 30/100, value 41/100. Its strongest factor is value.
BLRX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $14.03M
- Revenue (TTM)
- $1.40M
- P/E
- —
- EPS
- -0.00
- Dividend yield
- —
- Beta (5Y)
- 0.71
- 52-week high
- ₪0.02
- 52-week low
- ₪0.01
- Avg volume (3M)
- —
- Shares outstanding
- 2.62B
- Employees
- 22
- Next earnings
- —
About BioLineRx Ltd.
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
- ISIN
- IL0011015182
- Founded
- 2003
- Listed since
- Feb 6, 2007
- Exchange
- The Tel-Aviv Stock Exchange
- Currency
- ILS
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.